Affiliation:
1. Nutrition and Health Research Institute, COFCO Corporation, Beijing 102209, China
Abstract
Background:
Antimicrobial peptides (AMPs) are promising alternative agents for
antibiotics to overcome antibiotic resistance problems. But, it is difficult to produce large-scale antimicrobial research due to the toxicity towards expression hosts or degradation by peptidases in
the host. Therefore, heterologous recombinant expression of antimicrobial peptides has always
been a challenging issue.
Objective:
To overcome toxicity to the expression host and low expression level, a new photocleavable protein fusion expression method for antimicrobial peptides is provided.
Methods:
Through directed evolution and high throughput screening, a photocleavable protein mutant R6-2-6-4 with a higher photocleavage efficiency was obtained. The DNA coding sequence of
antimicrobial peptide Histatin 1 was fused within the sequence of R6-2-6-4 gene. The fusion gene
was successfully expressed in Escherichia coli expression system.
Results:
Antimicrobial peptide Histatin 1 could be successfully expressed and purified by fusing
within PhoCl mutant R6-2-6-4. The antimicrobial activity was rarely affected, and the MIC value
was 33 ug/mL, which was basically equivalent to 32 ug/mL of the chemically synthesized Histatin
1. After amplification in a 5 L fermenter, the expression of PhoCl mutant (R6-2-6-4)-Histatin1 improved up to 87.6 mg/L in fermenter, and Histatin1 obtained by photocleavage also could up to 11
mg/L. The prepared Histatin1 powder remained stable when stored at 4oC for up to 4 months without any degradation. In addition, the expression and photocleavage of β -Defensin105 and Lysostaphin verified the certain universality of the PhoCl mutant fusion expression system.
Conclusion:
Antimicrobial peptides Histatin 1, β -Defensin 105 and Lysostaphin were successfully expressed and purified by photocleavable protein mutant. This may provide a novel strategy to
express and purify antimicrobial peptides in the Escherichia coli expression system.
Publisher
Bentham Science Publishers Ltd.
Reference91 articles.
1. Chatterjee A.; Modarai M.; Naylor N.R.; Boyd S.E.; Atun R.; Barlow J.; Holmes A.H.; Johnson A.; Robotham J.V.; Quantifying drivers of antibiotic resistance in humans: A systematic review. Lancet Infect Dis 2018,18(12),e368-e378
2. Barton M.D.; Hart W.S.; Public health risks: Antibiotic resistance - review -. Asian-Australas J Anim Sci 2001,14(3),414-422
3. Ventola C L; The antibiotic resistance crisis: Part 1: Causes and threats P and T: A Peer Reviewed Journal for Formulary Management 2015,40(4),277-283
4. Davies J.; Davies D.; Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010,74(3),417-433
5. Carmeli Y.; Strategies for managing today’s infections. Clin Microbiol Infect 2008,14(s3)(Suppl. 3),22-31